China gains importance in global rare disease trials, Fortrea says
FTRE•Fortrea says regulatory reforms, expanded clinical infrastructure and large patient populations are increasing China’s role in global rare disease trials.
1. China’s trial role
Fortrea says regulatory reforms are enabling China to participate earlier in international rare disease development. It says expanded clinical infrastructure and access to large patient populations strengthen China’s appeal to global trial sponsors, while early regulatory engagement, biospecimen planning and specialized site selection can support startup timelines and study performance.
